Health Financing - Publications - Faculty & Research - Harvard Business School

Filter Results: (402)

Filter Results: (402)

Show Results For

← Page 2 of 402 Results →

Are you looking for?

→Search All HBS Web

August 2023
Supplement

Parexel (B): The Future of the CRO Industry

By: Regina E. Herzlinger and Ben Creo

How should Parexel respond to the rapidly changing environment in clinical research, now that it is owned by a private equity firm and its founder is no longer with the firm?

Parexel, a major clinical research organization, has experienced substantial... View Details

Keywords: New Technology; Strategic Evolution; Innovation; Health Testing and Trials; Research and Development; Private Equity; Private Ownership; Organizational Change and Adaptation; Health Industry

Summer 2023
Article

Do Policies to Increase Access to Treatment for Opioid Use Disorder Work?

By: Eric Barrette, Leemore S. Dafny and Karen Shen

Even among commercially insured individuals, opioid use disorder is undertreated in the United States: nearly half receive no treatment within six months of a new diagnosis. Using a difference-in-differences specification exploiting the extension of insurance parity... View Details

Keywords: Opioid Treatment; Medication-assisted Treatment; Substance Use Disorder; Private Insurance; Insurance; Health Care and Treatment

Find at Harvard

June 2023
Supplement

Roche: ESG and Access to Healthcare

By: George Serafeim

In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that... View Details

June 2023 (Revised November 2023)
Case

Sober Sidekick

By: Jeffrey J. Bussgang and Kumba Sennaar

Case on the nascent business model of a mobile health IT startup. In particular, should they pivot away from their successful lead generation business model to charging health plans. View Details

Keywords: Entrepreneurship; Venture Capital; Operations; Business Startups; Business Model; Health Industry; United States

April 2023 (Revised January 2024)
Background Note

Note on Healthcare in Ghana

By: Regina E. Herzlinger and Ben Creo

This note provides an overview of the healthcare system in Ghana. It discusses the public and private sector as well as traditional medical practice. It also discusses the country’s pharmaceutical industry. It is recommended as a companion to Professor Regina... View Details

Keywords: Africa; Pharmaceutical Companies; Pharmacy Benefit Manager; Health Care; Health Care Costs; Health Care Delivery; Health Care Entrepreneurship; Telehealth; Health Equity; Governing Rules, Regulations, and Reforms; Health Care and Treatment; Business and Government Relations; Health Industry; Health Industry; Ghana

May 4, 2023
Article

Falling Insulin Prices—What Just Happened?

By: Leemore S. Dafny

Recently, more than 100 years after insulin was developed, manufacturers announced price reductions for insulin products. Pressure to reduce prices had long been building, so why would they act now? View Details

Keywords: Price; Health Care and Treatment; Public Opinion; Demand and Consumers; Pharmaceutical Industry

Find at Harvard

Register to Read

April 2023 (Revised July 2023)
Case

Fermenting Accounting Problems at Vermont Kombucha Corp.

By: Tatiana Sandino and Marshal Herrmann

Founded in 2005, Vermont Kombucha Corp. (V-Ko) was an early mover in the fledgling U.S. market for kombucha, a drink brewed for its health benefits. Early on, the company captured more than 90% of market share. Under the leadership of its founder and CEO, Joe Williams,... View Details

Keywords: Going Public; Business Model; Financial Reporting; Ethics; Corporate Governance; Stock Shares; Food and Beverage Industry

April 5, 2023
Article

We Need an Operation Warp Speed for Long COVID

By: Esther K. Choo and Scott Duke Kominers

With millions of people affected and at least $1 trillion of economic value at stake, long COVID is our next national health emergency. View Details

Keywords: COVID; COVID-19; COVID-19 Pandemic; Scientific Research; Policy; Health Policy; Innovation; Science; Public Finance; Public Health; Health Disorders; Health Care and Treatment; Human Capital

March 2023 (Revised March 2024)
Case

The Purdue Pharma Bankruptcy: Settling the Opioid Crisis

By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney

How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details

March 2023
Case

Roche: ESG and Access to Healthcare

By: George Serafeim, Susanna Gallani and Benjamin Maletta

In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that... View Details

2023
Article

Comparison of COVID-19 Hospitalization Costs across Care Pathways: A Patient-level Time-driven Activity-based Costing Analysis in a Brazilian Hospital

By: Ricardo Bertoglio Cardoso, Miriam Allein Zago Marcolino, Milena Soriano Marcolino, Camila Felix Fortis, Leila Beltrami Moreira, Ana Paula Coutinho, Nadine Oliveira Clausell, Junaid Nabi, Robert S. Kaplan, Ana Paula Beck da Silva Etges and Carisi Anne Polanczyk

The COVID-19 pandemic raised awareness of the need to better understand where and how patient-level costs are incurred in health care organizations. This study used time-driven activity-based costing to estimate COVID-19 patient-level hospital costs in a Brazilian... View Details

Keywords: Health Care and Treatment; Cost; Health Industry; Brazil

February 2023
Article

A Different Framework to Achieve Universal Coverage in the U.S.

By: Katherine Baicker, Amitabh Chandra and Mark Shepard

This JAMA Forum discusses alternative ways to achieve universal coverage in the US such as administrative simplification in the Affordable Care Act plans to increase enrollment, having a basic policy that would be available to everyone, and options for supplemental... View Details

Keywords: Health Care and Treatment; Government Legislation; Insurance; Cost; United States

Register to Read

February 2024
Article

An Economic Framework for Vaccine Prioritization

By: Mohammad Akbarpour, Eric Budish, Piotr Dworczak and Scott Duke Kominers

We propose an economic framework for determining the optimal allocation of a scarce supply of vaccines that become gradually available during a public health crisis, such as the Covid-19 pandemic. Agents differ in observable and unobservable characteristics, and the... View Details

Keywords: Vaccine; Fairness; Public Finance; Public Goods; Allocation Problems; Allocative Efficiency; Allocation Rules; Social Welfare; Pandemics; Inequality; COVID-19; COVID-19 Pandemic; Public Sector; Resource Allocation; Market Design; Marketplace Matching; Public Administration Industry

January 2023
Teaching Note

Identify the Health Care Venture

By: Regina E. Herzlinger and James Wallace

Teaching Note for HBS Exercise No. 323-061. View Details

Keywords: Health Care; Health Care Delivery; Health Care Financing; Health Care Industry; Health Care Services

January 2023
Exercise

Identify the Health Care Venture

By: Regina E. Herzlinger and James Wallace

This case enables rapid learning of the key financial characteristics of many types of health care organizations and to diagnose their financial status. It is a surprisingly fun exercise (see the Teaching Note) accomplished by organizing groups of students that compete... View Details

Keywords: Health Care; Health Care Spending; Health Care Financing; Health Care Industry; Health Care Operations; Health Care Delivery; Health Care and Treatment; Financial Condition; Health Industry

January 2023
Teaching Note

The Opioid Settlement and Executive Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni

Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details

January 2023 (Revised September 2024)
Supplement

The END Fund (B)

By: V. Kasturi Rangan and Courtney Han

Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the... View Details

Keywords: Health Disorders; Investment Funds; Global Range; Nonprofit Organizations; Resource Allocation; Decisions; Health Care and Treatment; Mission and Purpose

January 2023
Case

The END Fund: To Eliminate Neglected Tropical Diseases

By: V. Kasturi Rangan and Courtney Han

Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the... View Details

Keywords: Nonprofit Organizations; Health Disorders; Health Care and Treatment; Resource Allocation; Global Range; Decisions; Investment Funds

January 2023
Case

Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery

By: Regina Herzlinger and Brian Walker

What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details

Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry

January 2023
Case

Thomas Buberl: Refounding AXA

By: Hubert Joly, Mihir Desai and Amram Migdal

In 2022, AXA and its CEO Thomas Buberl faced new types of challenges, including systemic risks such as climate change, geopolitical instability, public health crises, and social tensions caused by economic risks. AXA was one of the world’s largest insurers. Since... View Details

←
2
3
…
20
21
→